Citizens Business Bank Has $1.27 Million Stake in Amgen Inc. $AMGN

Citizens Business Bank increased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 92.5% in the 4th quarter, HoldingsChannel.com reports. The firm owned 3,864 shares of the medical research company’s stock after acquiring an additional 1,857 shares during the period. Citizens Business Bank’s holdings in Amgen were worth $1,265,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in AMGN. Board of the Pension Protection Fund acquired a new position in Amgen during the fourth quarter worth $26,000. Olistico Wealth LLC bought a new stake in Amgen during the fourth quarter worth $33,000. Cloud Capital Management LLC bought a new stake in Amgen during the third quarter worth $34,000. Ares Financial Consulting LLC bought a new stake in Amgen during the fourth quarter worth $34,000. Finally, Saranac Partners Ltd bought a new stake in Amgen during the third quarter worth $37,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

AMGN has been the topic of several analyst reports. Guggenheim upped their price target on shares of Amgen from $347.00 to $351.00 and gave the stock a “neutral” rating in a research report on Thursday, April 9th. Oppenheimer set a $400.00 price target on shares of Amgen and gave the stock an “outperform” rating in a research report on Thursday, January 29th. Rothschild & Co Redburn upped their price target on shares of Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a research report on Wednesday, February 18th. Piper Sandler upped their price target on shares of Amgen from $381.00 to $432.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 18th. Finally, Daiwa Securities Group upped their price target on shares of Amgen from $370.00 to $410.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 10th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Amgen presently has an average rating of “Hold” and an average target price of $356.62.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q1 results: Amgen reported EPS of $5.15 vs. consensus ~$4.74 and revenue of $8.62B vs. ~$8.58B — beats on both lines and sales rose ~4%, supporting the near?term earnings story. Amgen’s (NASDAQ:AMGN) Q1 CY2026 sales top estimates
• Positive Sentiment: Mgmt commentary/slides: Management framed 2026 as a “springboard” year and highlighted six growth drivers; investors may take this as confidence in product mix and pipeline execution. Amgen (AMGN) Q1 2026 Earnings Transcript
• Positive Sentiment: Pipeline progress: Amgen is advancing a broader development program for weight?loss candidate MariTide and submitted a label update to the FDA for an autoimmune drug — signs of R&D activity that could drive medium?term growth. Amgen sales rise 4% in first quarter, submits label update to FDA on autoimmune drug
• Neutral Sentiment: Guidance: FY?2026 EPS guidance set to 21.700–23.100 (consensus ~22.29); revenue guidance $37.1B–$38.5B (consensus ~37.8B) — range leaves room for beats or misses, which could sustain volatility as analysts model the year. Amgen Q1 press release and slide deck
• Neutral Sentiment: Analyst sentiment: Wall Street remains moderately optimistic on targets but Amgen has underperformed the market over the past year — analysts will reassess models after the quarter. What Are Wall Street Analysts’ Target Price for Amgen Stock?
• Negative Sentiment: Tavneos regulatory risk: An FDA advisory panel raised efficacy/data concerns for Tavneos and there have been reports of a proposed U.S. withdrawal — this is a material downside catalyst for a rare?disease franchise and could pressure sentiment until resolved. Amgen faces U.S. withdrawal of rare disorder therapy Tavneos

Amgen Price Performance

Shares of AMGN opened at $346.25 on Friday. The firm has a market capitalization of $186.86 billion, a PE ratio of 24.33, a PEG ratio of 3.34 and a beta of 0.47. The company’s 50-day moving average is $358.07 and its 200-day moving average is $340.45. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $391.29. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $4.73 by $0.42. The company had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company’s revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the firm earned $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities analysts forecast that Amgen Inc. will post 22.16 EPS for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be given a $2.52 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 2.9%. Amgen’s dividend payout ratio is presently 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.